Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2012-11-06 Earnings Release
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Cytos Biotechnology Ltd Reports Third Quarter 2012 Financial Results, Recent Development and Outlook
Earnings Release Classification · 100% confidence The document explicitly states in the title and body that it reports the 'Third Quarter 2012 Financial Results, Recent Development and Outlook'. This content structure, focusing on period-specific financial performance (Q3 2012) and business updates, aligns perfectly with the definition of an Interim/Quarterly Report (IR). Although it mentions a detailed Q3 Financial Report PDF link, the document itself is the press release summarizing those results, which is characteristic of an IR filing, rather than just an announcement of the report's publication (RPA). It is more comprehensive than a simple Earnings Release (ER) as it includes significant management changes and clinical trial updates alongside the financials. Q3 2012
2012-11-06 English
Cytos Biotechnology Ltd invites for an Extraordinary Shareholders' Meeting
AGM Information Classification · 98% confidence The document explicitly states, "Cytos Biotechnology Ltd invites for an Extraordinary Shareholders’ Meeting" and details the date, time, and purpose of the meeting (voting on a board member election). This content directly relates to the preparation and announcement of a shareholder meeting, which falls under the scope of AGM/EGM materials. Since the document is an invitation/announcement for a meeting where votes will be cast, the most appropriate classification is AGM-R (AGM Information), as it pertains to the meeting itself, rather than just the voting results (DVA) or the proxy materials (PSI). The document is a press release announcing the meeting, which is standard practice for AGM/EGM related announcements.
2012-10-26 English
Cytos Biotechnology Ltd appoints Dr. Christian Itin as Chief Executive Officer
Board/Management Information Classification · 100% confidence The document is a press release dated October 9, 2012, announcing the appointment of Dr. Christian Itin as the new Chief Executive Officer of Cytos Biotechnology Ltd. It also mentions changes to the Board of Directors and an upcoming Extraordinary Shareholders Meeting. This content directly relates to changes in senior management and board composition. According to the definitions, this falls under 'Board/Management Information' (Code: MANG). It is not an earnings release, a full annual report, or a proxy statement, but specifically a personnel change announcement.
2012-10-09 English
Cytos Biotechnology Ltd Reports Second Quarter 2012 Financial Results, Recent Development and Outlook
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the second quarter 2012 financial results for Cytos Biotechnology Ltd. It provides highlights of the results and business developments but explicitly directs the reader to an external URL to download the actual 'detailed Q2 Financial Report'. Following the 'Menu vs Meal' rule, since this document is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). Q2 2012
2012-07-30 English
Cytos Biotechnology Ltd Nominates Dr. Christian Itin, former President and CEO of Micromet Inc., as a Non-executive Director
Board/Management Information Classification · 100% confidence The document is a press release dated May 29, 2012, announcing the nomination of Dr. Christian Itin as a Non-executive Director to the Board of Directors and that the Board will propose his election at the next general meeting. This content directly relates to changes in senior management/board composition. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release (ER), a formal annual report (10-K), or a proxy statement (PSI) regarding voting materials, but rather an announcement about a future board proposal.
2012-05-29 English
Cytos Biotechnology Ltd Announces Updates to the Board of Directors
Board/Management Information Classification · 100% confidence The document is a press release titled "Cytos Biotechnology Ltd Announces Updates to the Board of Directors." The content explicitly details the new constitution and roles of the Board of Directors (e.g., Executive-Chairman, Vice Chairman, Committee members). This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2012-05-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.